LRMR vs. TVTX, OCS, ATXS, VERV, ANL, TRDA, KALV, APLT, LXRX, and YMAB
Should you be buying Larimar Therapeutics stock or one of its competitors? The main competitors of Larimar Therapeutics include Travere Therapeutics (TVTX), Oculis (OCS), Astria Therapeutics (ATXS), Verve Therapeutics (VERV), Adlai Nortye (ANL), Entrada Therapeutics (TRDA), KalVista Pharmaceuticals (KALV), Applied Therapeutics (APLT), Lexicon Pharmaceuticals (LXRX), and Y-mAbs Therapeutics (YMAB). These companies are all part of the "pharmaceutical preparations" industry.
Larimar Therapeutics (NASDAQ:LRMR) and Travere Therapeutics (NASDAQ:TVTX) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their community ranking, institutional ownership, analyst recommendations, risk, profitability, media sentiment, dividends, valuation and earnings.
Travere Therapeutics received 25 more outperform votes than Larimar Therapeutics when rated by MarketBeat users. However, 60.87% of users gave Larimar Therapeutics an outperform vote while only 48.62% of users gave Travere Therapeutics an outperform vote.
In the previous week, Larimar Therapeutics had 3 more articles in the media than Travere Therapeutics. MarketBeat recorded 8 mentions for Larimar Therapeutics and 5 mentions for Travere Therapeutics. Larimar Therapeutics' average media sentiment score of 0.84 beat Travere Therapeutics' score of 0.11 indicating that Larimar Therapeutics is being referred to more favorably in the media.
Larimar Therapeutics presently has a consensus price target of $20.00, suggesting a potential upside of 171.00%. Travere Therapeutics has a consensus price target of $16.69, suggesting a potential upside of 175.45%. Given Travere Therapeutics' higher probable upside, analysts clearly believe Travere Therapeutics is more favorable than Larimar Therapeutics.
Larimar Therapeutics has a beta of 0.96, suggesting that its stock price is 4% less volatile than the S&P 500. Comparatively, Travere Therapeutics has a beta of 0.69, suggesting that its stock price is 31% less volatile than the S&P 500.
91.9% of Larimar Therapeutics shares are owned by institutional investors. 4.3% of Larimar Therapeutics shares are owned by company insiders. Comparatively, 3.8% of Travere Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Larimar Therapeutics has a net margin of 0.00% compared to Travere Therapeutics' net margin of -87.94%. Larimar Therapeutics' return on equity of -35.69% beat Travere Therapeutics' return on equity.
Larimar Therapeutics has higher earnings, but lower revenue than Travere Therapeutics. Larimar Therapeutics is trading at a lower price-to-earnings ratio than Travere Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
Larimar Therapeutics beats Travere Therapeutics on 12 of the 17 factors compared between the two stocks.
Get Larimar Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for LRMR and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding LRMR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Larimar Therapeutics Competitors List
Related Companies and Tools
